Vikram Purohit
Stock Analyst at Morgan Stanley
(0)
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceut... | Maintains: Equal-Weight | 8 5 | 5.01 | -0.2% | 3 | Jun 16, 2025 | |
HALO Halozyme Therapeutic... | Downgrades: Equal-Weight | 73 62 | 52.24 | 18.68% | 7 | May 14, 2025 | |
ASND Ascendis Pharma | Upgrades: Overweight | 180 250 | 171.99 | 45.36% | 19 | May 5, 2025 | |
INCY Incyte | Maintains: Equal-Weight | 69 65 | 68.36 | -4.92% | 24 | Mar 24, 2025 | |
AXSM Axsome Therapeutics | Maintains: Overweight | 125 190 | 103.39 | 83.77% | 19 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 35 | 9.57 | 265.73% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 9 | 4.8 | 87.5% | 9 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 31 31 | 20.52 | 51.07% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 6 | n/a | n/a | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 2.62 | 167.18% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 7 | n/a | n/a | 16 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 15 16 | 7.4 | 116.22% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 2.77 | 983.03% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 22 | 9.15 | 140.44% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 10 | 13.73 | -27.17% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 46 6 | 2.35 | 155.32% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 43 42 | 8.4 | 400% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 10 | n/a | n/a | 4 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 23 | 1.22 | 1744.26% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 60 30 | n/a | n/a | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 3 | n/a | n/a | 2 | Jan 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 38 41 | 44.15 | -7.13% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 120 40 | 22.77 | 75.67% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 13 | 0.69 | 1784.06% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 39 38 | 20.61 | 84.38% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 24 20 | 11.4 | 75.44% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 10 | 11.21 | -10.79% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 7 | 29.62 | -76.37% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 1.43 | 1438.46% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 25 60 | n/a | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 40 20 | 9.21 | 117.16% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 2 | Mar 3, 2020 |